抗精神病药未用药个体中黑质磁共振成像与精神病严重程度关联的可推广性及样本外预测能力
该横断面研究在纽约招募42例未用药精神分裂症患者、53例临床高风险(CHR)个体和52名健康对照,并在墨西哥城16例未用药患者中外部验证。结果在精神分裂症中复制了黑质磁共振对比度与阳性症状严重程度的关联,CHR中未复制;交叉验证机器学习可预测严重程度且外部验证优于随机。
要点
- 精神分裂症中黑质磁共振对比度与PANSS阳性总分正相关(partial r=0.35)。
- CHR个体中未发现SIPS阳性总分与黑质磁共振对比度的显著关联(partial r=-0.08)。
- 交叉验证及外部验证显示黑质磁共振模式可预测精神病严重程度,优于随机。
核心结论
- 在未用药精神分裂症患者中复制了黑质磁共振对比度与精神病严重程度的样本内关联,但在CHR个体中未复制。
- 交叉验证机器学习分析证明黑质磁共振模式可用于预测新数据中的精神病严重程度,具有临床工具开发潜力。
研究设计与样本
- 横断面研究,2019至2023年从纽约地区招募主要样本(42例未用药精神分裂症、53例CHR、52名健康对照),从墨西哥城招募外部验证样本(16例未用药精神分裂症)。
- 共纳入163名参与者,76名(46.6%)为女性,平均年龄29.2岁(标准差10.4)。
临床怎么用
- 黑质磁共振成像作为精神病严重程度的潜在生物标志物,目前仍处于概念验证阶段,尚不宜直接用于临床决策。
- 在精神分裂症患者中可探索黑质磁共振预测阳性症状严重程度,但需进一步在独立样本中验证并标准化。
- 对CHR个体,黑质磁共振与症状严重程度的关联不显著,暂不能用于该人群的风险分层。
局限性
- 横断面设计无法推断因果关系。
- CHR样本中未复制关联,可能影响普适性。
- 外部验证样本量较小(16例),需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The link between psychosis and dopaminergic dysfunction is established, but no generalizable biomarkers with clear potential for clinical adoption exist. OBJECTIVE: To replicate previous findings relating neuromelanin-sensitive magnetic resonance imaging (NM-MRI), a proxy measure of dopamine function, to psychosis severity in antipsychotic-free individuals in the psychosis spectrum and to evaluate the out-of-sample predictive ability of NM-MRI for psychosis severity. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study recruited participants from 2019 to 2023 in the New York City area (main samples) and Mexico City area (external validation sample). The main samples consisted of 42 antipsychotic-free patients with schizophrenia, 53 antipsychotic-free individuals at clinical high risk for psychosis (CHR), and 52 matched healthy controls. An external validation sample consisted of 16 antipsychotic-naive patients with schizophrenia. MAIN OUTCOMES AND MEASURES: NM-MRI contrast within a subregion of the substantia nigra previously linked to psychosis severity (a priori psychosis region of interest [ROI]) and psychosis severity measured using the Positive and Negative Syndrome Scale (PANSS) in schizophrenia and the Structured Interview for Psychosis-Risk Syndromes (SIPS) in CHR. The cross-validated performance of linear support vector regression to predict psychosis severity across schizophrenia and CHR was assessed, and a final trained model was tested on the external validation sample. RESULTS: Of the 163 included participants, 76 (46.6%) were female, and the mean (SD) age was 29.2 (10.4) years. In the schizophrenia sample, higher PANSS positive total scores correlated with higher mean NM-MRI contrast in the psychosis ROI (t37 = 2.24, P = .03; partial r = 0.35; 95% CI, 0.05 to 0.55). In the CHR sample, no significant association was found between higher SIPS positive total score and NM-MRI contrast in the psychosis ROI (t48 = -0.55, P = .68; partial r = -0.08; 95% CI, -0.36 to 0.23). The 10-fold cross-validated prediction accuracy of psychosis severity was above chance in held-out test data (mean r = 0.305, P = .01; mean root-mean-square error [RMSE] = 1.001, P = .005). External validation prediction accuracy was also above chance (r = 0.422, P = .046; RMSE = 0.882, P = .047). CONCLUSIONS AND RELEVANCE: This study provided a direct ROI-based replication of the in-sample association between NM-MRI contrast and psychosis severity in antipsychotic-free patients with schizophrenia. In turn, it failed to replicate such association in CHR individuals. Most critically, cross-validated machine-learning analyses provided a proof-of-concept demonstration that NM-MRI patterns can be used to predict psychosis severity in new data, suggesting potential for developing clinically useful tools.
引用
- Wengler K, Baker SC, Velikovskaya A, et al. Generalizability and Out-of-Sample Predictive Ability of Associations Between Neuromelanin-Sensitive Magnetic Resonance Imaging and Psychosis in Antipsychotic-Free Individuals. JAMA Psychiatry. 2024. PMID: 37938847. doi:10.1001/jamapsychiatry.2023.4305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。